Galectin Therapeutics (GALT) Accumulated Expenses (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Accumulated Expenses of $4.2 million for Q1 2026, down 39.29% year-over-year from $6.9 million in Q1 2025, and down 11.35% quarter-over-quarter from $4.7 million in Q4 2025.
Galectin Therapeutics (GALT) Accumulated Expenses (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 39.29% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (down 39.29% YoY), while the FY2025 annual figure was $4.7 million, up 210.05% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $4.2 million, down from $4.7 million in the prior quarter.
- The five-year high for Accumulated Expenses was $10.9 million in Q2 2024, with the low at $386000.0 in Q1 2023.
- The 5-year median for Accumulated Expenses is $4.2 million (2026), against an average of $4.2 million.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses plunged 94.94% in 2023, then soared 2189.12% in 2024.
- Galectin Therapeutics' Accumulated Expenses stood at $973000.0 in 2022, then climbed by 16.03% to $1.1 million in 2023, then surged by 34.9% to $1.5 million in 2024, then surged by 210.05% to $4.7 million in 2025, then dropped by 11.35% to $4.2 million in 2026.
- Business Quant data shows GALT's Accumulated Expenses at $4.2 million in Q1 2026, $4.7 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.19 Mn |
| Dec 31, 2025 | 4.72 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 6.90 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | 10.86 Mn |
| Mar 31, 2024 | 8.84 Mn |
| Dec 31, 2023 | 1.13 Mn |
| Sep 30, 2023 | 7.84 Mn |
| Jun 30, 2023 | 7.91 Mn |
| Mar 31, 2023 | 386,000.00 |
| Dec 31, 2022 | 973,000.00 |
| Sep 30, 2022 | 751,000.00 |
| Jun 30, 2022 | 521,000.00 |
| Mar 31, 2022 | 7.63 Mn |
| Dec 31, 2021 | 728,000.00 |
| Sep 30, 2021 | 6.38 Mn |
| Jun 30, 2021 | 5.07 Mn |